Study of the Role of Genetic Modifiers in Hemoglobinopathies

Description

This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).

Conditions

Sickle Cell Disease, Thalassemia, Beta, Thalassemia Alpha, Hemoglobinopathies

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will investigate the role of genetic modifiers in hemoglobinopathies through a large-scale, multi-ethnic genome-wide association study (GWAS).

Study of the Role of Genetic Modifiers in Hemoglobinopathies

Study of the Role of Genetic Modifiers in Hemoglobinopathies

Condition
Sickle Cell Disease
Intervention / Treatment

-

Contacts and Locations

Boston

Boston Children's Hospital, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Clinical diagnosis of an inherited hemoglobinopathy, including sickle cell disease (SCD), β-thalassemia, and α-thalassemia; all genotypes will be considered.
  • * Age ≥ 2 years old at the time of the collection of the phenotypic data.
  • * There will be no limits on study participants in terms of gender, ethnicity, morbidities.
  • * Patients treated with stem cell transplantation or genetic therapy.
  • * Age \< 2 years old at the time of the collection of the phenotypic data.
  • * Patient or legal representative for minors unwilling or unable to give consent.

Ages Eligible for Study

2 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Cyprus Institute of Neurology and Genetics,

Petros Kountouris, PhD, PRINCIPAL_INVESTIGATOR, Cyprus Institute of Neurology and Genetics

Study Record Dates

2027-09-30